These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 20332023)

  • 21. Characterization of a double (amyloid precursor protein-tau) transgenic: tau phosphorylation and aggregation.
    Pérez M; Ribe E; Rubio A; Lim F; Morán MA; Ramos PG; Ferrer I; Isla MT; Avila J
    Neuroscience; 2005; 130(2):339-47. PubMed ID: 15664690
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Brief update on different roles of tau in neurodegeneration.
    Ittner A; Ke YD; van Eersel J; Gladbach A; Götz J; Ittner LM
    IUBMB Life; 2011 Jul; 63(7):495-502. PubMed ID: 21698753
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Raphé tauopathy alters serotonin metabolism and breathing activity in terminal Tau.P301L mice: possible implications for tauopathies and Alzheimer's disease.
    Menuet C; Borghgraef P; Matarazzo V; Gielis L; Lajard AM; Voituron N; Gestreau C; Dutschmann M; Van Leuven F; Hilaire G
    Respir Physiol Neurobiol; 2011 Sep; 178(2):290-303. PubMed ID: 21763469
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Deletion of murine tau gene increases tau aggregation in a human mutant tau transgenic mouse model.
    Ando K; Leroy K; Heraud C; Kabova A; Yilmaz Z; Authelet M; Suain V; De Decker R; Brion JP
    Biochem Soc Trans; 2010 Aug; 38(4):1001-5. PubMed ID: 20658993
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Proteomic analysis of serum proteins in triple transgenic Alzheimer's disease mice: implications for identifying biomarkers for use to screen potential candidate therapeutic drugs for early Alzheimer's disease.
    Sui X; Ren X; Huang P; Li S; Ma Q; Ying M; Ni J; Liu J; Yang X
    J Alzheimers Dis; 2014; 40(3):575-86. PubMed ID: 24496070
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tau pathology spread in PS19 tau transgenic mice following locus coeruleus (LC) injections of synthetic tau fibrils is determined by the LC's afferent and efferent connections.
    Iba M; McBride JD; Guo JL; Zhang B; Trojanowski JQ; Lee VM
    Acta Neuropathol; 2015 Sep; 130(3):349-62. PubMed ID: 26150341
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alzheimer's disease: genetic studies and transgenic models.
    Price DL; Tanzi RE; Borchelt DR; Sisodia SS
    Annu Rev Genet; 1998; 32():461-93. PubMed ID: 9928488
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutations causing neurodegenerative tauopathies.
    Goedert M; Jakes R
    Biochim Biophys Acta; 2005 Jan; 1739(2-3):240-50. PubMed ID: 15615642
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biochemical isolation of insoluble tau in transgenic mouse models of tauopathies.
    Julien C; Bretteville A; Planel E
    Methods Mol Biol; 2012; 849():473-91. PubMed ID: 22528110
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolic/signal transduction hypothesis of Alzheimer's disease and other tauopathies.
    Iqbal K; Grundke-Iqbal I
    Acta Neuropathol; 2005 Jan; 109(1):25-31. PubMed ID: 15645264
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Temporal memory deficits in Alzheimer's mouse models: rescue by genetic deletion of BACE1.
    Ohno M; Chang L; Tseng W; Oakley H; Citron M; Klein WL; Vassar R; Disterhoft JF
    Eur J Neurosci; 2006 Jan; 23(1):251-60. PubMed ID: 16420434
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular genetics of Alzheimer's disease and aging.
    Cacabelos R; Fernandez-Novoa L; Lombardi V; Kubota Y; Takeda M
    Methods Find Exp Clin Pharmacol; 2005 Jul; 27 Suppl A():1-573. PubMed ID: 16470248
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alzheimer's disease: transgenic mouse models and drug assessment.
    Yu P; Oberto G
    Pharmacol Res; 2000 Aug; 42(2):107-14. PubMed ID: 10887038
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tauopathy contributes to synaptic and cognitive deficits in a murine model for Alzheimer's disease.
    Stancu IC; Ris L; Vasconcelos B; Marinangeli C; Goeminne L; Laporte V; Haylani LE; Couturier J; Schakman O; Gailly P; Pierrot N; Kienlen-Campard P; Octave JN; Dewachter I
    FASEB J; 2014 Jun; 28(6):2620-31. PubMed ID: 24604080
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transgenic mouse models of Alzheimer's disease: phenotype and application.
    Higgins GA; Jacobsen H
    Behav Pharmacol; 2003 Sep; 14(5-6):419-38. PubMed ID: 14501255
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tau alteration and neuronal degeneration in tauopathies: mechanisms and models.
    Brandt R; Hundelt M; Shahani N
    Biochim Biophys Acta; 2005 Jan; 1739(2-3):331-54. PubMed ID: 15615650
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DNA Methylation in Genetic and Sporadic Forms of Neurodegeneration: Lessons from Alzheimer's, Related Tauopathies and Genetic Tauopathies.
    Zimmer-Bensch G; Zempel H
    Cells; 2021 Nov; 10(11):. PubMed ID: 34831288
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alzheimer's disease and amyloid: culprit or coincidence?
    Skaper SD
    Int Rev Neurobiol; 2012; 102():277-316. PubMed ID: 22748834
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Better Utilization of Mouse Models of Neurodegenerative Diseases in Preclinical Studies: From the Bench to the Clinic.
    Janus C; Hernandez C; deLelys V; Roder H; Welzl H
    Methods Mol Biol; 2016; 1438():311-47. PubMed ID: 27150098
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chronic administration of dimebon ameliorates pathology in TauP301S transgenic mice.
    Peters OM; Connor-Robson N; Sokolov VB; Aksinenko AY; Kukharsky MS; Bachurin SO; Ninkina N; Buchman VL
    J Alzheimers Dis; 2013; 33(4):1041-9. PubMed ID: 23099813
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.